Sign up
Pharma Capital

Zogenix stock plunges after FDA refuses to review seizure drug

In a refusal-to-file letter, the FDA pointed to an incorrect version of a dataset in the company’s application
brain and brain waves
Fintepla is a treatment for seizures associated with Dravet syndrome.

Zogenix Inc (NASDAQ:ZGNX) is reeling after the Food and Drug Administration late Thursday refused to review the company’s new drug application for Fintepla, a treatment for seizures associated with Dravet syndrome.

In a refusal-to-file letter, the FDA pointed to an incorrect version of a dataset in the Emeryville, California company’s application and the exclusion of certain non-clinical studies, which prevented the administration from completing a review.

The drugmaker is seeking a Type A – high priority – meeting with the FDA to address the concerns.

READ: Zogenix shares pop on impressive Phase 3 results for epilepsy drug

“We remain highly confident in Fintepla’s clinical profile demonstrated in the Phase 3 program in Dravet syndrome and are committed to advancing the product candidate as a potential new treatment option,” President and CEO Stephen J. Farr said. “We are fully committed to working with the FDA as quickly as possible to address the open issues and clarify the path to successfully re-filing our application.”

Shares plummeted more than 22% to $40.22.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

1551807154_andrew.jpg


Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.